Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2012

View Archived Issues

Phase I/II and phase II gene therapy trials conducted in patients with SCID

S1P1 receptor agonist shows efficacy in preclinical models of IBD

French researchers present new HSP 90 inhibitors

Eisai presents highlights of fiscal 2011

Novel candidate analgesic patented

Early clinical results presented for tralokinumab in asthma

A new small molecule inhibits dermal inflammation in mouse models

Human pharmacokinetic profile of RO-5458640 determined in monkeys

BMS investigators describe preclinical studies with antimigraine candidate

Phase I/II Xerecept results promising in children with cerebral tumors

Research at Presidio Pharmaceuticals yields new HCV inhibitors

U.S. government supports phase III smallpox vaccine study

Karolinska University Hospital and GE Healthcare enter research collaboration

Phase III HA-irinotecan study to continue enrollment

Novel imaging agents created to diagnose Alzheimer's disease

New AP-TNAP inhibitors presented in France

Catalyst reports topline data from phase Ia CPP-115 study

Unigene reports encouraging preclinical data on UGP-281

Novel ER-alpha agonists patented

FDA approves expanded use of Levemir

Chelsea Therapeutics discusses Northera complete response letter with FDA

Repros submits revised documentation to FDA for Androxal studies

NICE publishes guidance on rivaroxaban

Adva-27a shows superior pharmacokinetic profile than etoposide

Confirmatory U.S. phase III trial of Scenesse begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...